Profound Medical lands FDA OK for prostate cancer trial

September 18, 2013 by Brad Perriello

The FDA grants an investigational device exemption to Profound Medical for a clinical trial of its prostate cancer device.

Profound Medical lands FDA OK for prostate cancer trial

Profound Medical said it won an investigation device exemption from the FDA for a clinical trial of its device to treat prostate cancer.

The Toronto-based medical device company said it hopes to begin enrolling patients later this year in the Tulsa trial.

The Profound device combines thermal ultrasound with real-time MRI guidance in a single outpatient session to treat localized prostate cancer, according to a press release.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp